title: [A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib].
abstract: We administered gefitinib to a patient after considering his request to be treated with the drug. Fortunately, he responded favorably to the treatment and did not show signs of serious adverse effects or deterioration of renal functions. The patient was a 69-year-old male who visited an outpatient clinic because of chronic renal failure and was diagnosed with primary lung cancer. He then underwent an operation for lung cancer, but because it had progressed to stage IV the lesion was not completely resected. The patient was unable to receive effective chemotherapy due to the prior chronic renal failure. During best support care, the patient suffered from respiratory failure due to the tumor growth, and his quality of life (QOL) deteriorated. The patient was administered 250 mg of gefitinib orally, which was effective in reducing the tumor, improving his QOL, and prolonging his survival time. With the lack of literature on administering gefitinib to patients with chronic renal failure and evidence supporting the effectiveness of this treatment, the physician in charge should obtain the patient's informed consent before initiating treatment using this anticancer drug.
authors.affiliation: Dept. of Thoracic Surgery, Tokyo Kensei Hospital.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Takaoka
authors.forename: Bunpei
authors.initials: B
authors.lastname: Kimura
authors.forename: Akinori
authors.initials: A
authors.lastname: Aikawa
authors.forename: Syouji
authors.initials: S
authors.lastname: Tokimitsu
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Hashizume
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Kidokoro
authors.forename: Kan
authors.initials: K
authors.lastname: Katou
authors.forename: Tomoko
authors.initials: T
authors.lastname: Takano
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Yamagishi
authors.forename: Mika
authors.initials: M
authors.lastname: Uchikado
authors.forename: Syuuji
authors.initials: S
authors.lastname: Itou
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Okano
authors.forename: Yukie
authors.initials: Y
authors.lastname: Hanawa
authors.forename: Miyuki
authors.initials: M
authors.lastname: Yagi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000601:surgery; D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077156:Gefitinib; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011184:Postoperative Period; D011788:Quality of Life; D011799:Quinazolines / Q000627:therapeutic use*; D012131:Respiratory Insufficiency / Q000150:complications*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib